- Home
- SNDX vs DSL Comparison
SNDX vs DSL Comparison
Compare SNDX & DSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- DSL
- Stock Information
- Founded
- SNDX 2005
- DSL 2013
- Country
- SNDX United States
- DSL United States
- Employees
- SNDX N/A
- DSL N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- DSL Trusts Except Educational Religious and Charitable
- Sector
- SNDX Health Care
- DSL Finance
- Exchange
- SNDX Nasdaq
- DSL Nasdaq
- Market Cap
- SNDX 1.3B
- DSL 1.4B
- IPO Year
- SNDX 2016
- DSL N/A
- Fundamental
- Price
- SNDX $16.42
- DSL $12.22
- Analyst Decision
- SNDX Strong Buy
- DSL
- Analyst Count
- SNDX 10
- DSL 0
- Target Price
- SNDX $38.40
- DSL N/A
- AVG Volume (30 Days)
- SNDX 1.9M
- DSL 470.0K
- Earning Date
- SNDX 11-04-2025
- DSL 01-01-0001
- Dividend Yield
- SNDX N/A
- DSL 10.81%
- EPS Growth
- SNDX N/A
- DSL N/A
- EPS
- SNDX N/A
- DSL N/A
- Revenue
- SNDX $77,933,000.00
- DSL N/A
- Revenue This Year
- SNDX $642.36
- DSL N/A
- Revenue Next Year
- SNDX $108.58
- DSL N/A
- P/E Ratio
- SNDX N/A
- DSL N/A
- Revenue Growth
- SNDX 2126.66
- DSL N/A
- 52 Week Low
- SNDX $8.58
- DSL $10.58
- 52 Week High
- SNDX $22.50
- DSL $13.00
- Technical
- Relative Strength Index (RSI)
- SNDX 61.98
- DSL 41.42
- Support Level
- SNDX $14.93
- DSL $12.10
- Resistance Level
- SNDX $15.99
- DSL $12.38
- Average True Range (ATR)
- SNDX 0.70
- DSL 0.12
- MACD
- SNDX 0.04
- DSL -0.02
- Stochastic Oscillator
- SNDX 83.26
- DSL 29.27
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About DSL DoubleLine Income Solutions Fund of Beneficial Interests
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.